Encephalomyocarditis Virus Vaccines
Creative Biolabs is a world leader in the field of viral vaccine development. By consistently delivering the highest standards of quality, professionalism, and integrity, we want to become the partner of a choice for your requirements. With our extensive experience and advanced platform, we are therefore confident in offering the best vaccine development services for diseases caused by encephalomyocarditis virus. We guarantee the finest results for our customers all over the world.
Encephalomyocarditis virus (EMCV), a picornavirus associated with myocarditis in primates, is a pandemic virus that has caused mortality in numerous captive wildlife species worldwide. The viruses have been isolated from over 30 host species, including mammals, birds, and invertebrates. Natural transmission of EMCV in swine is likely due to ingestion of carcasses infected with EMCV animals, usually mice or rats, or ingestion of food or water contaminated by EMCV-positive carcasses. Commonly considered a rodent pathogen, EMCV is known in the swine industry and caused severe economic losses on pig production due to high mortality in piglets as a result of myocarditis and sudden death and in sows as a result of severe reproductive failure.
There are several types of vaccine against EMCV are under development include inactivated EMCV vaccine, DNA vaccine and combination vaccine.
Inactivated EMCV Vaccines
An inactivated EMCV vaccine produced by the baculovirus expression system has been created. The vaccine was tested for safety and efficacy and the results indicate that this vaccine is a safe option that would provide high antigenicity and immunogenicity in swine. Besides, a novel EMCV vaccine composed of killed EMCV mixed with an alum adjuvant was understudied that is safe to use during sow gestation and induces and maintains high levels of seroconversion. The inactivated virus with alum adjuvant could be a candidate for protecting against EMCV induced reproductive failure in pig farms.
DNA Vaccine against EMCV
DNA vaccine was designed with recombinant VP1 protein of EMCV from Escherichia coli, and eukaryotic VP1 expression vector. In this model, mice were immunized intramuscularly with vaccine in the presence or absence of plasmid DNA expressing granulocyte-macrophage colony stimulating factor (GM-CSF). Their anti-VP1 immune responses with recombinant VP1 were subsequently analyzed by ELISA. Compared with a single DNA injection, coinjection of mice with the DNA vaccine and plasmid DNA encoding GM-CSF was shown a higher seroconversion rate of the immunized mice and enhanced to a higher degree VP1-specific immunity, which appeared to result in better protection (about 80%) from EMCV challenge. Therefore, the results provide evidence for the potential use of GM-CSF to induce better immune response and resistance against EMCV infection in DNA vaccination.
Combination Vaccine against EMCV
A combination vaccine mixed EMCV and porcine circovirus type 2 (PCV2) against both EMCV and PCV2 is highly desirable created. These two viruses are common causative agents with high infection rate in pig farms. An oil-adjuvant combination vaccine candidate comprising of inactivated EMCV and PCV2 was developed and evaluated the safety and immunogenicity in mice and swine. The experiment data shows this vaccine could elicit serum antibodies and has strong neutralization activity which protects swine against either EMCV or PCV2 lethal infections. The combined vaccine was safe and induced protective immune response in mice and swine which can be an option in vaccines against EMCV.
Creative Biolabs is a highly proactive, robust, and diversified company with a strong, scientifically-proven background of viral vaccine development. We have experts who are able to help you with the vaccine development against poliomyelitis caused by EMCV. If you are interested in our services, please contact us for more details.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
